With New Mechanism, Can Eisai’s Fycompa Make Its Mark In Epilepsy?
Executive Summary
Efficacy results were not uniformly positive in pivotal trials of newly approved perampanel, but FDA explains that may be due to high placebo rates in some international sites.
You may also be interested in...
A Pillar Of Eisai’s Growth Strategy Misses Primary Endpoint In First Phase III Trial
Eisai-acquired Morphotek lead candidate farletuzumab sees disappointing results in platinum-sensitive ovarian cancer.
German Joy For Pharma As Drug Discount Prices Stay Hidden
The updated German Pharmaceutical Act will ensure that drug prices negotiated there between pharmaceutical manufacturers and health insurers will remain hidden from public view, as Germany’s government seeks to avoid a pan-European drug price crash.
Epilepsy NMEs: A View Of The Playing Field
The late-stage pipeline for novel epilepsy treatments stars a handful of specialty and foreign firms, but the early-stage lineup makes room for new firms and the products of academic research. Venture philanthropy is a big factor, but the poor funding climate for CNS firms may limit play.